NervGen Pharma Corp Overview
Pro stress-test →NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The company's lead candidate, NVG-291, is a first- and potential best-in-class candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with spinal cord injury.
Strategic Profile
Pro stress-test →NVG-291 was granted Fast Track designation by the FDA in October 2023 and Orphan Drug designation by the European Medicines Agency for the treatment of SCI in February 2021. The company plans to hold an FDA End-of-Phase 2 meeting in early 2026 to align on the development pathway for NVG-291, with enrollment of individuals with subacute SCI in the Phase 1b/2a CONNECT SCI Study ongoing and preparation for a Phase 3 clinical trial in chronic SCI.
Competitive Landscape
Pro stress-test →NervGen is pursuing a rare therapeutic space—first-in-class pharmacologic therapy for spinal cord injury. The company has plans to advance NVG-291 toward potential approval as the first pharmacologic therapy for SCI. Primary competition comes from larger pharma and biotech firms with broader neurology pipelines, but limited direct competitors in spinal cord regeneration.
Industry Context
NervGen Pharma Corp operates in Clinical-stage biopharmaceuticals / Neuroreparative therapeutics.
Key facts
Founded: 2017 · Headquarters: Vancouver, Canada · Employees: N/A · Revenue: CAD $0 · Market cap: CAD $469-479M